Atara Biotherapeutics stock plunges after FDA rejects cancer therapy

AbbVie in up to $5.6B deal with RemeGen for bispecific antibody for solid tumors

Published On : 2026-01-12

AbbVie in up to $5.6B deal with RemeGen for bispecific antibody for solid tumors

#Business

Atara Biotherapeutics stock plunges after FDA rejects cancer therapy

Published On : 2026-01-12

Atara Biotherapeutics stock plunges after FDA rejects cancer therapy

#Business

Subscribe to get the latest posts sent to your email.

Trend Teller